Every 10-Q that Gentherm Inc (THRM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow THRM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full THRM filings page.
Gentherm Incorporated reported Q2 2026 product revenues of $416,166 (thousands), up from $375,090 a year earlier. Net income was $4,420 versus $477, or $0.14 per diluted share. For the first half, revenues totaled $809,872 and net income $8,638 (all in thousands).
Automotive drove nearly all growth, while Medical posted an operating loss. Q2 operating income declined to $10,689 as higher selling, general and administrative costs and increased restructuring charges offset gross profit gains. Operating cash flow for the first half fell to $2,272 from $31,701, largely reflecting higher receivables and working-capital uses, though cash on hand rose to $213,173 at June 30.
Strategically, Gentherm closed the $34,000 purchase of Innovative Medical Equipment on July 1, 2026 and is pursuing a Reverse Morris Trust with Modine’s Performance Technologies business valued at about $1,000,000, expected to close by early Q4 2026. Debt increased to $273,258, including $260,000 drawn on a $550,000 revolver now maturing in 2031. Multiple restructuring programs continue, with at least $9,000 of expected cash costs under the 2026 Plan and a restructuring liability of $12,770. The board replaced a $150,000 repurchase authorization with a larger $400,000 program through July 2029. Gentherm also outlines auto-part recall exposures with Volkswagen and Porsche that could be material, though no amounts are yet estimable.
Gentherm Incorporated reported Q1 2026 product revenue of $393.7 million, up 11.3% year over year, as Automotive sales rose across Climate Control Seats, lumbar and massage systems, and other comfort products. Gross margin improved slightly to 24.7% and net income reached $4.2 million, or $0.14 per diluted share, versus a small loss a year ago.
Operating income fell to $11.3 million as selling, general and administrative costs jumped, largely from $14.8 million of Modine merger and acquisition expenses and higher restructuring charges. The company ended the quarter with $177.4 million in cash, $219.0 million drawn on its revolving credit facility, and outlined a planned Reverse Morris Trust combination with Modine’s Performance Technologies business valued at about $1.0 billion.
Gentherm (THRM) reported Q3 results for the period ended September 30, 2025. Product revenue was $386,870, with gross margin of $95,148 and operating income of $23,858. Net income was $14,949, or diluted EPS of $0.49. Interest expense, net, was $3,313, and the effective tax rate was 28.4%.
For the nine months, operating cash flow reached $87,820, ending cash and cash equivalents were $154,250. Total debt was $189,109, primarily the U.S. dollar revolving credit facility at $189,000; $307,938 remained available for additional borrowings. Letters of credit outstanding were $3,062.
The company advanced multi‑region restructuring to optimize its manufacturing footprint. The 2025 Manufacturing Footprint Plan anticipates cash restructuring costs of $3,000–$4,000 for severance and $1,000 of other transition costs, plus $1,000–$2,000 of capital expenditures. The 2025 EMEA Plan expects $4,000–$6,000 for severance and $2,000–$3,000 of other costs, plus $1,000–$2,000 of capital expenditures. The 2025 Asia Plan expects $2,000–$3,000 for severance and $1,000 of other costs, plus $2,000–$3,000 of capital expenditures. As of October 17, 2025, shares outstanding were 30,525,148; year‑to‑date repurchases totaled $10,015, with $110,103 remaining under the authorization.